This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Lilly Announces Dr. Lechleiter's Return

INDIANAPOLIS, July 8, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that John C. Lechleiter, Ph.D., has returned to his duties as chairman, president, and chief executive officer.  Lechleiter has been on medical leave since his scheduled surgery for a dilated aorta on May 13, 2013. Lechleiter's surgery and recovery were successful and he has been cleared by his personal physician and the company's employee health services physician to return to full-time work.

"I am overwhelmed and humbled by the tremendous support and well-wishes I have received from my friends and fellow Lilly colleagues around the world," Lechleiter said.  "I return to Lilly with renewed energy and enthusiasm, along with a new perspective on health and wellness and the critical importance of new medicines in advancing patient care.

"I want to thank and acknowledge Derica Rice for the important role he played during my absence, as well as Ellen Marram for her leadership of the Lilly board," added Lechleiter.

Derica W. Rice will continue in his role as executive vice president, global services and chief financial officer.  Rice had assumed the additional role of acting chief executive officer during Lechleiter's medical leave.  Ellen R. Marram will continue in her role as the board's lead independent director after serving as acting chairperson of the board of directors during Lechleiter's medical leave.

About Eli Lilly and CompanyLilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at C-LLY

Refer to: (317) 433-9899 – Edward Sagebiel;               (317) 276-5795 – Mark Taylor;

(Logo: )

SOURCE Eli Lilly and Company

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,868.06 +77.87 0.46%
S&P 500 1,990.38 +10.46 0.53%
NASDAQ 4,772.20 +23.8390 0.50%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs